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Abstract
Background: The secreted protein acidic and rich in cysteine (SPARC) plays a pivotal role in regulating cell-matrix 
interactions and tumor angiogenesis, proliferation, and migration. Detection of SPARC gene methylation may be useful 
as a tumorigenesis marker for early detection of pancreatic cancer.
Methods: Methylation of the SPARC gene transcriptional regulation region (TRR) was detected using bisulfite-specific 
(BSP) PCR-based sequencing analysis in 40 cases of pancreatic cancer and the adjacent normal tissues, 6 chronic 
pancreatitis tissues, and 6 normal pancreatic tissues. BSP cloning-based sequencing analysis was also performed in 
selected cases. Clinicopathological data from the cancer patients were collected and analyzed.
Results: Analysis of SPARC gene TRR methylation showed two hypermethylation wave peak regions: CpG Region 1 
(CpG site 1-7) and CpG Region 2 (CpG site 8-12). Pancreatic tissues have shown methylation in both regions with 
gradual increases from normal, chronic pancreatitis, and adjacent normal tissues to cancerous tissues. However, 
Methylation of CpG Region 2 was more sensitive than CpG Region 1 in pancreatic tumorigenesis. Furthermore, the 
methylation level of CpG Region 2 was associated with increased tumor size and exposure to the risk factors (tobacco 
smoke and alcohol consumption) for developing pancreatic cancer.
Conclusion: Methylation of the SPARC gene, specifically CpG Region 2, may be an early event during pancreatic 
tumorigenesis and should be further evaluated as a tumorigenesis marker for early detection of pancreatic cancer.
Background
Pancreatic cancer, one of the highly invasive and
extremely lethal neoplasms, is the fifth leading cause of
cancer death in the United States [1]. Pancreatic cancer
mortality almost parallels its incidence, with a 5-year sur-
vival rate of less than 4%. Although surgical resection
remains the only hope for long-term survival in patients
with pancreatic cancer, the majority (~85%) of patients
are found to be unresectable at diagnosis due to extensive
local invasion and/or metastatic disease [2]. Therefore,
early detection of pancreatic cancer is the key for improv-
ing survival of patients. Unfortunately, no early-detection
markers currently are available for early diagnosis of pan-
creatic cancer, although many scientists are pursuing
pancreatic cancer research and believe that early detec-
tion of pancreatic cancer using molecular gene markers
may be possible in the future [3,4].
To date, it is clear that many genetic and epigenetic
alterations occur during pancreatic tumorigenesis [5].
Among these alterations, methylation of the tumor sup-
pressor gene promoter results in gene silencing [6], which
may take place during the very early stages of pancreatic
c a n c e r  d e v e l o p m e n t .  D e t e c t i o n  o f  s u c h  a b e r r a n t  D N A
methylation of tumor suppressor genes could be used as a
diagnostic marker for pancreatic cancer [7]. Thus, defin-
ing altered gene expression and understanding the under-
lying molecular mechanism in pancreatic cancer are
urgently needed.
Secreted protein acidic and rich in cysteine (SPARC)/
osteonectin/BM 40 is a matricellular glycoprotein that is
involved in diverse biological processes, including tissue
remodeling, wound repair, morphogenesis, cell differenti-
ation, proliferation, migration, and angiogenesis [8-11]. A
previous study showed that the SPARC gene promoter is
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aberrantly methylated in primary pancreatic cancer tis-
sue [12]. Gene expression profiling using oligonucleotide
microarray and reverse transcription-PCR analyses dem-
onstrated that SPARC mRNA was expressed in non-neo-
plastic pancreatic ductal epithelial cells but not in the
majority of pancreatic cancer cell lines [12]. The condi-
tioned medium containing secreted SPARC protein sup-
pressed the growth of pancreatic cancer cells, indicating
that silencing of the SPARC gene may result in pancreatic
cancer development and progression [12].
In the current study, we detected the methylation levels
and methylation pattern of the SPARC  gene transcrip-
tional regulation region (TRR) in normal, adjacent nor-
mal, chronic pancreatitis, and pancreatic cancer tissues to
assess the altered methylation levels of the SPARC gene
to determine if SPARC methylation can be used as a tum-
origenesis marker for the early detection of pancreatic
cancer.
Methods
Cell line and culture
Pancreatic cancer cell line PANC1 was purchased from
the American Type Culture Collection (Manassas, VA,
USA) and PaTu8988 was a kind gift from Dr. H.P. Elsasser
(Phillips University, Marburg, Germany). These cells
were grown in Dulbecco's modified Eagle's medium
(DMEM) supplemented with 10% fetal bovine serum
(both were from Life Technologies Inc., Rockville, MD,
USA) and incubated at 37°C in a humidified chamber
with 95% air and 5% CO2.
Patient tissue specimens
A tissue and patient's data usage protocol was approved
by the Ethics Committee of our institution. Informed
written consent was obtained from each patient. Tissue
samples from 52 patients were obtained from the Second
Military Medical University affiliated Changhai Hospital
from August 2006 to December 2007; these samples were
from 6 pathologically proven cases of chronic pancreati-
tis, 6 cases of normal pancreatic tissues, 40 cases of pan-
creatic cancer (ductal adenocarcinoma type), and
corresponding normal tissue from those same 40
patients. The tissue samples were obtained and stored in
liquid nitrogen immediately after being resected in the
operating room. For pancreatic cancer cases, tumor tis-
sues that contained more than 70% tumor cells and the
corresponding adjacent normal tissues without any
tumor cell infiltration were selected. In addition, samples
of white blood cells (WBCs) were obtained from two
healthy volunteers. Clinicopathological data, including
gender, age, status of tobacco smoking and alcohol con-
sumption, tumor size, differentiation, lymph node metas-
tasis, and TNM stages, were collected from the electronic
medical records of the patients. Tobacco smoking was
defined as at least one cigarette per day for no less than 1
year. Alcohol consumption was defined as intake of at
least 50 ml of Chinese liquor, 250 ml of wine, or 500 of ml
beer at least once a week for a minimum of 1 year. The
6th American Joint Committee on Cancer (AJCC) staging
system was used to classify the clinical stage of pancreatic
cancer.
DNA extraction and bisulfite modification of DNA
Genomic DNA from the tissues and cell lines was
extracted using the phenol/chloroform method and pre-
cipitated with ethanol. One microgram of genomic DNA
was subjected to treatment with the EZ DNA Methyla-
tion Kit™ (Zymo Research, Orange, CA, USA) according
to the manufacturer's instructions. The bisulfite modified
DNA was then suspended in 20 μl of deionized water and
used immediately or stored at -80°C until use.
Bisulfite-specific (BSP) PCR and DNA sequencing
The primers used to detect methylation of the SPARC
gene promoter TRR were designed to specifically amplify
bisulfite-converted DNA of SPARC  TRR. The primers
were 5'-ATTTAGTTTAGAGTTTTG-3' (forward) and 5'-
ACAAAACTTCCCTCCCTTAC-3' (reverse) and were
custom synthesized by Shanghai Sangon (Shanghai,
China). Two microliters of the bisulfite modified DNA
from each sample were subjected to PCR analysis in a 25
μL volume containing 1 × PCR buffer, 2.0 mmol/L MgCl2,
2.5 mmol/L dNTP, 1 mmol/L primer, and EX Taq DNA
HS 800 U/L. The reaction mixture was preheated at 95°C
for 5 min and amplified using a touch-down PCR pro-
gram (i.e., 9 cycles of 95°C for 30 s, 59°C for 30 s (next
cycle touch-down 0.5°C) and 72°C for 30 s; 42 cycles of
95°C for 30 s, 55°C for 30 s, and 72°C for 30 s; and a final
extension of 4 min at 72°C. The PCR products were then
subjected to either direct sequencing analysis or cloning
into the pMD-18-T vector (TaKaRa, Dalian, China) fol-
lowed by sequencing analysis (after the cloning, 10-25
c l o n e s  f r o m  e a c h  s a m p l e  w e r e  r a n d o m l y  s e l e c t e d  f o r
DNA sequencing).
Sequencing data analysis
Sequencing analysis was performed by Shanghai Invitro-
gen Biotech Co. Ltd (Shanghai, China). For the data
obtained from BSP PCR-based sequencing analysis, the
percentage of methylation of each C pG site in a given
s a m p l e  w a s  c a l c u l a t e d  a s  t h e  h e i g h t  o f  t h e  " C "  p e a k
divided by the sum of the height of "C" + "T". For the data
obtained from BSP cloning-based sequencing analysis,
the percentage of methylation of each CpG site in a given
sample was calculated as the number of the methylated
CpG sites divided by the total observed sequenced clone
numbers. The percentage of the region methylation in aGao et al. Journal of Experimental & Clinical Cancer Research 2010, 29:28
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given sample was the average of each CpG site in the
DNA region.
Statistical analysis
Statistical analyses were conducted using SPSS version
15.0 (SPSS, Chicago, IL, USA). A one-way ANOVA test
was performed to analyze differences in the percentage of
the region methylation among pancreatic cancer tissues,
adjacent normal pancreatic tissues, chronic pancreatitis
tissues, and normal pancreatic tissues. General linear
model univariate analysis was performed to determine
the correlations of SPARC methylation with clinical char-
acteristics of pancreatic cancer. All variables were subse-
quently analyzed using a stepwise multiple regression to
assess their independent contribution to the methylation
level, with entry and removal at the 0.05 and 0.1 signifi-
cance levels, respectively.
Results
Methylation of the SPARC gene TRR in pancreatic tissues 
and pancreatic cancer cells
According to the NCBI genome database, we analyzed
the SPARC gene TRR and found a CpG island around the
transcriptional start site (designated as '0') between the
upstream -29 bp and downstream +191 bp using the
methylation analysis software of Methyl Primer Express
v1.0 (ABI). Figure 1A illustrates the structure of the
SPARC gene and the topology of the BSP primer, indicat-
ing the position of the CpG island containing 12 CpG
sites and the BSP primers.
We next performed BSP PCR-based sequencing analy-
sis to assess the methylation status of the SPARC gene
TRR in four tissue groups: 40 pancreatic cancer samples
and their corresponding adjacent normal pancreatic tis-
sues, 6 chronic pancreatitis samples, and 6 real normal
pancreatic tissue samples. Figure 1B shows representative
BSP PCR-based sequencing analysis results for these four
different groups of pancreatic tissues. The methylation
pattern of the SPARC gene TRR in these four types of
pancreatic tissues is shown in Figure 2. According to the
curve fitted to the mean percent methylation of pancre-
atic cancer tissue data by the MACD (moving average
convergence/divergence) method, we found two hyperm-
ethylation wave peak regions in these CpG islands. The
first contained CpG site 1-7 (CpG Region 1) and the sec-
ond contained CpG sites 8-12 (CpG Region 2). We
searched the web site http://www.cbrc.jp/research/db/
TFSEARCH.html and found that CpG Region 1 con-
tained two Sp1 sites while CpG Region 2 contained one
Ap1 site (Figure 1A). Figure 3 shows the mean percentage
of gene methylation and the 95% CI of these two hyperm-
ethylation wave peak regions in the four types of pancre-
atic tissues. Methylation of these two regions appeared to
gradually increase from normal, chronic pancreatitis, and
adjacent normal to pancreatic cancer tissues. Further-
more, CpG Region 2 was rarely methylated in real normal
Figure 1 Detection of SPARC gene TRR methylation. (A) Illustration 
of the SPARC gene TRR and topology of the BSP primer. The black bar 
indicates the analyzed region. The bold "G" indicates the transcription-
al start site. The bold italic "CG" indicates the location of 12 CpG island 
sites. The underlined sequence indicates the primers for BSP. Blue and 
red rectangles indicate the Sp1 and AP1 binding consensus sequenc-
es, respectively. The red triangles indicate the region whose represen-
tative sequence analyses were showed in Figure 1B. (B) Representative 
sequencing data of the SPARC gene TRR in four different groups of 
pancreatic tissues obtained using BSP PCR-based sequencing analysis. 
CpG dinucleotides "C" in the objective sequence are shown in red. The 
red, yellow, green, light blue, and deep blue dots under the analyzed 
sequence represent different methylation ratios, respectively.
Figure 2 Methylation pattern of the SPARC gene TRR in pancreat-
ic tissue samples. The pattern consists of two hypermethylation wave 
peak regions including CpG region 1 (CpG site 1--7) and CpG region 2 
(CpG site 8--12). The curve was fitted to the mean methylation ratios of 
pancreatic cancer tissues using the MACD (moving average conver-
gence/divergence) method.Gao et al. Journal of Experimental & Clinical Cancer Research 2010, 29:28
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Figure 3 Methylation level of CpG region 1 (A) and CpG region 2 (B) in the SPARC gene TRR in pancreatic tissues. All data are reported as means 
± 95% CI. #, the pancreatic cancer tissues are compared to the corresponding tumor adjacent normal tissues, chronic pancreatitis tissues, or normal pan-
creatic tissues, p < 0.05. &, the corresponding tumor adjacent normal tissues are compared to the real normal pancreatic tissues, p < 0.05.Gao et al. Journal of Experimental & Clinical Cancer Research 2010, 29:28
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pancreatic tissues but CpG Region 1 was more frequently
methylated in some of normal tissues. In addition, the
methylation level of CpG Region 2 in the adjacent normal
tissues was significantly increased compared with the
normal tissues. These results indicate that methylation of
CpG Region 2 may be a more sensitive marker and an
early event during pancreatic tumorigenesis.
To further confirm that hypermethylation of the
SP ARC gene TRR occurs in pancreatic cancer , we also
performed BSP cloning-based sequencing analysis in two
pancreatic cancer cell lines (PANC1 and Patu8988), three
cases of pancreatic cancer and adjacent normal tissues,
two cases of normal pancreatic tissues, and two cases of
WBCs from healthy volunteers. Figure 4 shows the meth-
ylation pattern of the SPARC gene TRR in these samples.
The two pancreatic cancer cell lines and two-thirds of the
pancreatic cancer tissues (PC09 and PC179, but not
PC186) obviously presented two hypermethylation wave
peak regions (CpG Region 1 and CpG Region 2) in the
CpG islands compared to the adjacent normal and nor-
mal tissues and the WBCs from the healthy volunteers.
These data confirmed the results of the BSP PCR-based
sequencing analysis.
Association of SPARC gene TRR methylation with 
clinicopathological parameters in patients with pancreatic 
cancer
We collected clinicopathological data from the patients
and then analyzed the association of SPARC gene TRR
methylation with clinicopathological parameters in
patients with pancreatic cancer. General linear model
univariate analysis showed that the percentage of CpG
Region 2 methylation was associated with larger tumor
size, tobacco smoking, and alcohol consumption (Table
1). Multiple regression analysis also showed that the fac-
tors of larger tumor size, tobacco smoking, and alcohol
consumption were independent contributors to the per-
centage of CpG Region 2 methylation (Table 2).
Discussion
In the current study, we determined the methylation sta-
tus of the SPARC gene promoter in pancreatic cancer cell
lines, pancreatic cancer and corresponding adjacent nor-
mal pancreatic tissues, chronic pancreatitis tissues, and
real normal pancreatic tissues. Methylation of the SPARC
gene TRR gradually increased from normal, chronic pan-
creatitis, and the adjacent normal tissues to pancreatic
cancer tissues. The methylation pattern of the SPARC
gene TRR exhibited two hypermethylation wave peak
regions: CpG Region 1 (CpG site 1-7) and CpG Region 2
(CpG site 8-12). CpG Region 2 was rarely methylated in
real normal pancreatic tissues but CpG Region 1 was
more frequently methylated. In addition, the methylation
level of CpG Region 2 in the adjacent normal tissues was
significantly increased compared with the real normal tis-
sues. Furthermore, the aberrant hypermethylation of
CpG Region 2 was associated with larger tumor size,
tobacco smoking, and alcohol consumption. Our results
indicated that methylation of CpG Region 2 could be fur-
ther evaluated as a tumorigenesis marker for the early
diagnosis of pancreatic cancer.
It is known that chronic pancreatitis is considered to be
a precancerous lesion [13] and that cancer-adjacent tis-
sues experience "the field effect of carcinogenesis," which
is evident because they show the same genetic changes as
the tumor [14,15]. In this study, we found that CpG
Region 2 was hypermethylation in corresponding tumor
adjacent normal pancreatic tissues and chronic pancrea-
titis tissues, and additionally that its hypermethylation
correlated with pancreatic cancer risk factors (tobacco
smoking and alcohol consumption) [13,16]. These data
showed that hypermethyhlation of CpG Region 2 is an
early event in pancreatic cancer tumorigenesis.
Brune et al. demonstrated that aberrant methylation of
the SPARC gene promoter as a marker of sporadic pan-
creatic adenocarcinoma can also be used to detect famil-
ial pancreatic adenocarcinoma [7]. Sato et al. showed that
the SPARC gene promoter was methylated in pancreatic
cancer juice with sensitivity of 90.9% and specificity of
70.4% for pancreatic cancer diagnosis [17]. These studies
utilized a conventional MSP method to detect SPARC
gene methylation. In the current study, we not only con-
firmed the published data about methylation of the
SPARC gene promoter in pancreatic cancer, but we also
further revealed the methylation level of the different
sites of the CpG island. In particular, our data showed
that the methylation pattern of the SPARC  gene TRR
exhibited two hypermethylation wave peak regions. The
methylation level of CpG Region 1 was higher in pancre-
atic cancer tissue than in normal, chronic pancreatitis,
and the adjacent normal tissues, but CpG Region 1 of the
SPARC gene also was methylated in normal pancreatic
tissues. In contrast, CpG Region 2 was only methylated in
pancreatic cancer, adjacent normal, and chronic pancrea-
titis tissues. These data suggest that methylation of CpG
Region 2 is a more sensitive marker to detect early altera-
tion in pancreatic cancer.
Aberrant methylation of the SPARC  gene has been
reported in various kinds of tumors, including lung and
colorectal cancer, acute myeloid leukemia, multiple
myeloma, endometrial cancer, ovarian cancer, cervical
cancer, pancreatic cancer, and prostate cancer [18-25].
I n f a n t e  e t  a l .  r e po rt ed  t h a t  t h e r e  w e r e  f o u r  e x p r e s s i o n
patterns of the SPARC gene in pancreatic cancer tissues:
tumor-/stroma- (16%); tumor+/stroma- (17%); tumor-/
stroma+ (52%); and tumor+/stroma+ (15%) [26]. Sato et
al. reported that SPARC mRNA was expressed in non-
neoplastic pancreatic ductal epithelial cells (79%) but notGao et al. Journal of Experimental & Clinical Cancer Research 2010, 29:28
http://www.jeccr.com/content/29/1/28
Page 6 of 9
in pancreatic cancer cell lines (0/17) or the majority of
primary pancreatic cancer tissues (68%) and that methy-
lation of the SPARC gene promoter was responsible for
gene silencing [12].
The molecular mechanism responsible for methylation
of the SPARC gene promoter is unknown. Recent studies
demonstrated that some environmental factors (such as
tobacco smoke) can cause methylation of certain tumor
suppressor genes [14,27]. In pancreatic cancer, tobacco
smoke can induced k-ras gene mutation and p16 and
ppENK gene methylation [28,29]. Our data showed that
exposure to risk factors such as tobacco smoke and alco-
hol use was associated with methylation of CpG Region 2
in the SPARC gene promoter in pancreatic cancer tissues.
Our data may indicate that these risk factors cause pan-
creatic cancer development and progression through
induction of SPARC gene methylation.
The SPARC gene may play a role in suppression of tum-
origenesis, including pancreatic cancer. Molecularly, the
SPARC protein binds to a number of different extracellu-
lar matrix components, such as thrombospondin 1, vit-
ronectin, entactin/nidogen, fibrillar collagens (types I, II,
III, and V), and collagen type IV. SPARC has the potential
to contribute to the organization of the matrix in connec-
Figure 4 Methylation status of 12 CpG island sites and the methylation level of CpG Region 1 and CpG Region 2 in the samples determined 
using BSP cloning-based sequencing analysis. BSP cloning-based sequencing analysis was performed on real normal pancreatic tissues (N4 and 
N7), white blood cells (W6 and W8) of two healthy volunteers, pancreatic cancer cell lines (PANC1 and Patu8988), pancreatic cancer tissues (PC09, 
PC179, and PC186), and the corresponding adjacent normal tissues (PN09, PN179, and PN186). Black dot, methylated; white dot, unmethylated.Gao et al. Journal of Experimental & Clinical Cancer Research 2010, 29:28
http://www.jeccr.com/content/29/1/28
Page 7 of 9
tive tissue as well as basement membranes to regulate
cell-cell interaction and differentiation to modulate cell
growth. However, to date, it remains to be determined
whether SPARC is a tumor suppressor gene or an onco-
gene. It is because both kinds of data were published and
available in Pubmed. Particularly, two papers showed that
SPARC wasn't expressed in the majority of primary pan-
creatic cancer tissues (68%~69%)[12,26], whereas another
s t u d y  f o u n d  h i g h  e x p r e s s i o n  o f  S P A R C  i n  a l m o s t  a l l
tumour tissues [30]. Furthermore, all these three papers
reported strong staining of SPARC in fibroblasts and the
extracellular matrix. Moreover, Podhajcer et al. [31]
reported that SPARC gene expression was associated
with good prognosis. In addition, the in vitro experiment
showed that the expression of SPARC inhibited growth of
cancer cells [12,30], but promoted invasion of pancreatic
tumor cells [30]. Another study, however, showed that
inhibition of endogenous SPARC enhanced pancreatic
cancer cell growth [32]. In our current study, we found
that methylation of the SPARC gene is an early event dur-
ing pancreatic carcinogenesis, which supports the prem-
ise that this gene is a tumor suppressor gene. Although
we didn't show expression data of SPARC, it is obvious
that methylation of gene promoter surely silences the
gene expression. Taken altogether, this discrepancy war-
rants further investigation.
Regulation of gene expression by the de novo methyla-
tion is involved in tumorigenesis [33]. De novo methyla-
tion is a progressive process rather than a single event
and is neither site specific nor completely random but
Table 1: Correlations of SPARC methylation with clinical characteristics of pancreatic cancer
Clinical 
characteristics
Cases 
(n = 40)
Methylation ratio (%)
Region 1 p Region 2 p Total p
Gender
Male 25 58.6 ± 11.8 0.709 53.6 ± 18.7 0.265 56.5 ± 11.9 0.337
Female 15 59.8 ± 12.1 55.5 ± 22.6 58.0 ± 13.2
Age (yrs)
≤ 55 19 58.0 ± 12.0 0.386 52.6 ± 19.1 0.156 55.7 ± 12.1 0.142
> 55 21 60.0 ± 11.7 56.0 ± 21.0 58.3 ± 12.6
Alcohol
-- 20 58.7 ± 12.9 0.794 46.6 ± 18.2 0.016 53.7 ± 11.2 0.154
+ 20 60.0 ± 11.7 62.1 ± 19.1 60.5 ± 12.6
Smoking
-- 22 58.1 ± 13.7 0.671 47.5 ± 17.5 0.017 53.7 ± 11.9 0.067
+ 18 60.2 ± 9.1 62.8 ± 19.1 61.3 ± 11.7
Tumor size (cm)
≤ 2 21 55.4 ± 10.5 0.087 46.1 ± 18.8 0.029 51.5 ± 10.1 0.013
> 2 19 63.1 ± 12.0 63.5 ± 17.4 63.3 ± 11.7
Differentiation
Moderate 19 59.6 ± 12.2 0.625 53.6 ± 20.4 0.799 57.1 ± 12.4 0.877
Poor 21 58.6 ± 11.6 55.0 ± 20.1 57.1 ± 12.5
Lymph node 
metastasis
-- 23 60.4 ± 12.4 0.307 53.7 ± 20.0 0.832 57.6 ± 12.5 0.421
+ 17 57.2 ± 10.9 55.2 ± 20.7 56.4 ± 12.3
pTNM stage
I+II 21 58.2 ± 12.4 0.444 51.9 ± 20.1 0.867 55.5 ± 12.6 0.543
III+IV 19 60.0 ± 11.2 57.1 ± 20.0 58.8 ± 12.0
Correlations of SPARC methylation with clinical characteristics of pancreatic cancer were determined by general linear model univariate 
analysis.Gao et al. Journal of Experimental & Clinical Cancer Research 2010, 29:28
http://www.jeccr.com/content/29/1/28
Page 8 of 9
instead is region specific. Recognition and methylation of
differentially methylated regions by DNA methyltrans-
ferase involves the detection of both nucleosome modifi-
cation and CpG spacing, giving rise to methylation in a
periodic pattern on the DNA [34]. On the other hand,
many researchers have found that transcription factors
(e.g., c-Myb, c-Myc/Myn, E2F, CREB, Ap1, Ap2, Sp1, and
NF-κB) are incapable of binding to methylated DNA of
their recognition sequences and that gene transcription
therefore is blocked [35,36]. The identification of region-
specific methylation patterns in genes may be essential
for an accurate assessment of methylation-mediated tran-
scriptional silencing [37]. In this study, two Sp1 and one
AP1 sites were identified in the SPARC gene TRR and the
AP1 site is localized at CpG Region 2 (covering CpG site
10 and CpG site11). However, the biological significance
of these SP1 and AP1 sites in the SPARC gene will require
further study.
In summary, our current data demonstrated different
methylation levels of the SPARC  gene TRR CpG sites.
Methylation of CpG Region 2 was more sensitive than
CpG Region 1 in pancreatic tumorigenesis, suggesting
that aberrant hypermethylation of CpG Region 2 may be
useful as a tumorigenesis marker for early detection of
pancreatic cancer. However, this finding needs to be veri-
fied in a study with a larger sample size of patients with
pancreatic cancer.
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Table 2: The standardized coefficient beta value of multiple regression analysis
Clinical characteristics Region 1 Region 2 Whole region
Gender -- -- --
A g e - -- -- -
Alcohol -- 0.341 (p = 0.012) --
Smoking -- 0.336 (p = 0.013) --
Tumor size 0.332 (p = 0.036) 0.342 (p = 0.013) 0.485 (p = 0.002)
Differentiation -- -- --
Lymph node metastasis -- -- --
p T N M  s t a g e - -- -- -
Adjusted R2 0.087 0.367 0.215
Clinical characteristics of pancreatic cancer were analyzed using a stepwise multiple regression to assess their independent contribution to 
the methylation level, with entry and removal at the 0.05 and 0.1 significance levels, respectively.Gao et al. Journal of Experimental & Clinical Cancer Research 2010, 29:28
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